10x Genomics Reports Disappointing Q3 Results

PLEASANTON, Calif. – 10x Genomics, Inc. (NASDAQ: TXG) reported third-quarter results that fell short of expectations, with shares declining by 7.79% in after-hours trading on Tuesday.

The single-cell and spatial biology company posted revenue of $151.7 million for the quarter, missing analyst estimates of $158.84 million and representing a 1% year-over-year decrease. Adjusted earnings per share came in at -$0.30, beating expectations of -$0.34.

10x Genomics attributed the revenue shortfall to greater-than-anticipated disruption from a sales restructuring implemented during the quarter, as well as cautious customer spending. The company also lowered its full-year 2024 revenue guidance to $595-$605 million, down from its previous outlook of $640-$660 million.

> "Our results this quarter fell short of our expectations given greater-than-anticipated disruption from the sales restructuring we implemented in the quarter and cautious customer spending," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "As these dynamics persist, especially under a difficult macro backdrop, our revenue growth this year will be lower than our previous expectations."

The company's gross margin improved to 70% from 62% in the year-ago quarter, primarily due to changes in product mix. Operating expenses decreased 22% year-over-year to $147.9 million.

10x Genomics highlighted the launch of several new products during the quarter, including GEM-X Flex (NASDAQ: FLEX), which enables researchers to run millions of cells for less than one cent per cell, and Chromium Xo, a budget-friendly instrument for routine single-cell analysis.

Despite near-term challenges, Saxonov expressed confidence that the steps being taken will enable the company to reach more customers and drive broader adoption of its technologies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.